Workflow
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss

Group 1 - LENZ Therapeutics, Inc. reported a quarterly loss of $0.53 per share, which was better than the Zacks Consensus Estimate of a loss of $0.58, representing an earnings surprise of +8.62% [1] - The company posted revenues of $5 million for the quarter ended June 2025, in line with the Zacks Consensus Estimate, compared to zero revenues a year ago [2] - LENZ Therapeutics shares have increased approximately 9.7% since the beginning of the year, outperforming the S&P 500's gain of 8.3% [3] Group 2 - The earnings outlook for LENZ Therapeutics will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The estimate revisions trend for LENZ Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.70 on revenues of $5.63 million, and -$2.72 on revenues of $8.8 million for the current fiscal year [7] Group 3 - The Medical - Biomedical and Genetics industry, to which LENZ Therapeutics belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]